<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039442</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0128G</org_study_id>
    <secondary_id>NCI-2012-02469</secondary_id>
    <secondary_id>CDR0000069384</secondary_id>
    <secondary_id>GOG-0128G</secondary_id>
    <secondary_id>GOG-0128G</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00039442</nct_id>
  </id_info>
  <brief_title>Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer</brief_title>
  <official_title>A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of capecitabine in treating patients who have&#xD;
      persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the antitumor activity of capecitabine in patients with persistent or recurrent&#xD;
      non-squamous cell carcinoma of the cervix who have failed higher priority treatment&#xD;
      protocols.&#xD;
&#xD;
      II. Determine the nature and degree of toxicity of this drug in these patients. III.&#xD;
      Determine whether the mRNA tumor expression levels of thymidylate synthase (TS),&#xD;
      dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) at baseline are&#xD;
      potential predictors of clinical outcomes (response and survival) in patients treated with&#xD;
      this drug.&#xD;
&#xD;
      IV. Determine whether the serum level of TP is a potential prognostic indicator of clinical&#xD;
      outcomes (response and survival) in patients treated with this drug.&#xD;
&#xD;
      V. Determine whether the TS promoter polymorphism in peripheral blood is a potential&#xD;
      prognostic indicator of clinical outcomes (response and survival) in patients treated with&#xD;
      this drug.&#xD;
&#xD;
      VI. Determine the associations among the various measures of TS, DPD, and TP and clinical&#xD;
      outcomes (response and survival) in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2002</start_date>
  <primary_completion_date type="Actual">December 7, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events, graded according to CTC version 2.0</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of objective response</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of observed adverse events, graded according CTC version 2.0</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Cervical Adenosquamous Carcinoma</condition>
  <condition>Recurrent Cervical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed primary non-squamous cell carcinoma (non-SCC) of the cervix&#xD;
&#xD;
               -  Persistent or recurrent disease&#xD;
&#xD;
               -  Eligible subtypes include:&#xD;
&#xD;
                    -  Adenocarcinoma&#xD;
&#xD;
                    -  Adenosquamous cell carcinoma&#xD;
&#xD;
                    -  Undifferentiated carcinoma&#xD;
&#xD;
          -  Documented disease progression&#xD;
&#xD;
          -  At least 1 unidimensionally measurable target lesion outside prior irradiation field&#xD;
&#xD;
               -  At least 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT scan,&#xD;
                  and MRI)&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
          -  Received 1 prior systemic chemotherapy regimen for advanced, metastatic, or recurrent&#xD;
             non-SCC of the cervix&#xD;
&#xD;
               -  Radiosensitizing chemotherapy administered in combination with primary&#xD;
                  radiotherapy is not counted as a systemic chemotherapy regimen&#xD;
&#xD;
          -  Tissue blocks from initial diagnosis, metastasis, or recurrence available for&#xD;
             submission to the GOG tissue bank&#xD;
&#xD;
          -  Ineligible for higher priority Gynecologic Oncology Group (GOG) protocol (if one&#xD;
             exists), defined as any Temporarily closed GOG phase III protocol for the same patient&#xD;
             population&#xD;
&#xD;
          -  Performance status - GOG 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No Temporarily closed infection requiring antibiotics&#xD;
&#xD;
          -  No grade 2 or greater sensory or motor neuropathy&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  At least 3 weeks since prior biological or immunological anticancer agents&#xD;
&#xD;
          -  No more than 1 prior non-cytotoxic biologic therapy or cytostatic regimen (e.g.,&#xD;
             monoclonal antibodies, cytokines, or small-molecule inhibitors of signal transduction)&#xD;
             for recurrent or persistent non-SCC of the cervix&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No prior capecitabine&#xD;
&#xD;
          -  No more than 1 prior cytotoxic chemotherapy regimen (either with single or combination&#xD;
             cytotoxic drug therapy)&#xD;
&#xD;
          -  At least 1 week since prior hormonal anticancer therapy&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Recovered from prior recent surgery&#xD;
&#xD;
          -  At least 3 weeks since other prior anticancer therapy&#xD;
&#xD;
          -  No prior cancer treatment that would preclude this study therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Look</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

